Loading
Loading
Metabolic & Body Composition · 90mg
Choose dose
Janoshik-tested · 10 vials per kit
Tirzepatide is a dual GLP-1 and GIP receptor agonist studied in clinical research for its metabolic effects. Research has examined its potential to modulate blood glucose, enhance insulin secretion, inhibit glucagon release, and improve insulin sensitivity. Studies indicate it may outperform single GLP-1 agonists in HbA1c reduction and weight loss, with additional effects on blood pressure, lipid metabolism, and adiponectin levels.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor co-agonist — a 39-amino-acid synthetic peptide engineered to activate both glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor with balanced nanomolar potency at each. Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), it represents the second generation of incretin-based research compounds beyond GLP-1 monoagonists.
Unlike selective GLP-1 agonists, tirzepatide simultaneously engages GIPR — a receptor with distinct downstream biology from GLP-1R. GIPR activation on adipocytes may paradoxically potentiate the appetite-suppressing effects of co-administered GLP-1R engagement. Centrally, dual receptor activation produces greater reductions in food reward and caloric intake than either agonist alone. Metabolically, the combination drives additive glucose-lowering through both insulin secretion and direct adipose tissue effects.
The SURMOUNT and SURPASS clinical programmes demonstrated body weight reductions of up to 22.5% at 72 weeks (SURMOUNT-1) — exceeding prior GLP-1 monoagonist results. Ongoing research encompasses sleep apnoea, heart failure with preserved ejection fraction (SUMMIT trial), non-alcoholic steatohepatitis, chronic kidney disease, and type 1 diabetes adjunct therapy.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
